EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

Japan is seeing a record boom in tourism, but one recent visitor travelled more than the circumference of the earth to get ...

Steve Lee Hayes carved letters onto a pillar of a gate of a shrine in Shibuya and was arrested on suspicion of property ...

A 65-year-old American tourist has been arrested in Japan for carving letters into a wooden gate at a shrine in Tokyo.

Report with market evolution powered by AI - The global wound care market size is estimated to grow by USD 6.95 billion from ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

TOKYO (Kyodo) -- A single course of newly approved ... the treatment in Japan of early symptomatic Alzheimer's disease.

Prime Minister Shigeru Ishiba, whom lawmakers voted to keep in office Monday despite his party’s dismal recent election showing, has vowed to further strengthen the U.S.-Japan alliance.

From the Edo-Tokyo Museum Collection,” is currently touring Japan. We asked the exhibition’s curator, Koyama Shuko, from the ...